We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at ...

Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna’s cost-reduction plans, pipeline cuts and reined-in financial guidance, unveiled Thursday, triggered a wave of ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...